An excellent presentation from Prof Tom Foltynie followed by an examining Q &A session from the audience, probing further into the benefits of these drugs, giving real-time trial updates and some testimony from some PwP actually on the trial giving us a real insight.

Professor Tom Foltynie is Professor of Neurology in the Department of Clinical and Movement Neurosciences, UCL Institute of Neurology & Consultant Neurologist at the National Hospital for Neurology and Neurosurgery, Queen Square, London.

He is responsible for Movement disorder patients, particularly Parkinson’s disease (PD) patients undergoing advanced treatments such as Deep Brain Stimulation (DBS), Apomorphine and Duodopa.

He is chief investigator for a series of trials of Exenatide- a potential neurorestorative treatment for PD, as well as the lead clinician at UCL for trials of alpha-synuclein vaccination for PD and Oxford Biomedica/ Axovant’s gene therapy product for PD, and the Transeuro PD cell transplantation program.

You can follow Prof Foltynie on Twitter https://twitter.com/foltynie

You can find out more from Prof Foltynie here:-

https://www.ucl.ac.uk/ion/research/ou...

https://www.uclh.nhs.uk/our-services/...

https://www.michaeljfox.org/researche...

https://www.youtube.com/watch?v=WozwO...

Want alerts for future speaker sessions?
Email us at [email protected]

You can follow us on social media
Instagram:- https://www.instagram.com/nosilverbul...
Twitter:- https://twitter.com/NSB4PD